The Gut Fungus That’s More Common in IBS Patients, Yet Tied to Milder Pain

If you have IBS (irritable bowel syndrome) and have ever wondered whether something living in your gut is making things better or worse, a new study offers a genuinely counterintuitive answer: possibly both, from the same organism. Researchers at Peking University sequenced the fungi lining the colon in people with diarrhea-predominant IBS and found one genus, Cladosporium, a common environmental mold, showed up more often in patients than in healthy volunteers. That alone would fit the usual dysbiosis story: more of a strange organism, more disease. But the same team found the opposite pattern for symptoms: patients who carried more Cladosporium reported milder abdominal pain, not worse. When they tested the fungus directly in mice, it calmed gut pain rather than causing it.

Key takeaways

• Cladosporium, a mold genus, was more abundant in the colon lining of IBS patients than in healthy controls, but patients carrying more of it reported milder pain (correlation of -0.76).
• Feeding mice a reference strain of Cladosporium cladosporioides reduced gut pain sensitivity, normalized stool water content, and calmed overactive mast cells, immune cells that help drive gut pain.
• The mechanism traces to a receptor called dectin-1: the fungus dampened dectin-1 signaling in mouse colons and in human mast cells grown in a dish.
• This is early, small, and animal-based; it is not a reason to seek out mold exposure or a Cladosporium supplement, and the authors say the human causal link is still unproven.

Cladosporium Abundance in the Gut Tracks With Milder IBS Symptoms

The core finding, published in the World Journal of Gastroenterology, is that Cladosporium was the fungal genus that best separated the colonic mucosa of IBS patients from healthy controls, and that its abundance correlated inversely with symptom severity (r = -0.76). The researchers used ITS sequencing, a genetic method that identifies fungi the way 16S sequencing identifies bacteria, on tissue taken directly from the colon lining during colonoscopy, rather than from stool, because mucosal fungi sit closer to the gut wall and immune cells than fungi just passing through. A related genus, Cryptococcus, was more abundant in the healthy controls. To confirm the fungus was doing something rather than just riding along, the team gavaged (fed via tube) mice with C. cladosporioides and found it suppressed an immune receptor called dectin-1, which normally helps mast cells recognize fungi and mount an inflammatory response.

Why This Matters for the Roughly 1 in 10 People Who Have IBS

IBS affects an estimated 7% to 21% of people worldwide, according to the study's own framing of prior literature, and more than 60% of diagnosed patients show visceral hypersensitivity (VH), a heightened, painful sensitivity to normal gut sensations that is considered a core driver of IBS symptoms and a reason many patients don't respond well to standard treatment. Most microbiome research on IBS has focused on bacteria; the fungal side, known as the gut mycobiome, has been comparatively neglected, partly because fungi are far less abundant in the gut and harder to sequence reliably. This study adds specific weight to the idea that individual fungal species, not just "fungal overgrowth" in general, can matter, and that at least one common environmental mold might behave as a protective presence rather than a threat. If confirmed, it would reframe how researchers think about restoring gut balance in IBS-D (diarrhea-predominant IBS) specifically.

How the Study Was Designed, and Where It Got Thin

The human portion enrolled 36 IBS-D patients and 29 matched healthy controls at Peking University First Hospital, using colonoscopy-collected mucosal tissue and Rome IV diagnostic criteria for IBS. But fungal DNA is scarce in mucosal tissue, and usable sequencing libraries were only successfully built for 14 patient samples and 12 control samples, roughly a 60% dropout from the enrolled group. The Cladosporium enrichment itself was only borderline after statistical correction for multiple comparisons (adjusted P = 0.079), and the striking -0.76 correlation with symptom severity rests on just 14 patients. The mouse experiments used a TNBS-induced model, a chemical method of triggering IBS-like gut inflammation and pain sensitivity in animals, with four groups of 7 mice each. Gut pain was measured using graded balloon distension of the rectum at four pressures, scored on a standard 0-4 behavioral scale. C. cladosporioides significantly reduced pain scores at only one of those four pressures (60 mmHg), though it also normalized stool water content and fecal frequency, which had been abnormal in the TNBS group.

What This Could Mean for Someone Managing IBS

Nothing here supports seeking out mold exposure or taking a Cladosporium supplement, and the study's own authors are explicit that the strain gavaged into mice was a standard laboratory reference strain (ATCC 6721), never isolated from an actual patient, and that "the direct causal link in humans remains to be established." What the findings do support is a shift in how to think about gut fungi generally: the assumption that more of an unfamiliar organism automatically means more disease does not hold here. For someone with IBS-D and treatment-resistant pain, the practical takeaway right now is limited to awareness, not action, this is a mechanism worth discussing with a gastroenterologist as mycobiome-focused diagnostics mature, not a supplement to add to a routine. The involvement of mast cells, immune cells already known to sit near gut nerve endings and release pain-triggering compounds like tryptase and histamine in IBS, gives this a plausible mechanistic story, but plausible is not proven.

What's Still Unresolved

The biggest open question is direction: does Cladosporium abundance rise because the body is compensating for pain in a defensive attempt to calm things down, as the authors speculate, or does it play some other role entirely? The correlational human data cannot distinguish cause from effect, and the study never isolated and cultured the actual Cladosporium strain living in patients' guts, so no one yet knows whether the ATCC lab strain used in mice behaves the same way a patient's own strain would. The mechanism proposed, that the fungus fails to fully activate dectin-1 and thereby avoids triggering the mast cell inflammatory cascade, is drawn partly from prior literature rather than fully demonstrated fresh in this paper.

What Comes Next

The authors call for fecal fungal transfer experiments and interventions using strains isolated directly from patients, rather than a generic reference strain, to separate a genuine protective effect from mere association. Multi-omics and metabolomite studies are also flagged as necessary to identify which specific fungal molecules, candidates include compounds called cladosporone A and ergosterol peroxide, are doing the biological work. No human treatment trial exists yet, and the study was funded entirely through public grants from the Natural Science Foundation of Beijing Municipality and Peking University First Hospital, with the authors reporting no conflicts of interest.

Common Questions

Does this mean mold exposure helps IBS? No. The study looked at a specific mucosal fungal genus already living in the gut, not environmental mold exposure through air or damp buildings, and the authors explicitly do not recommend deliberate exposure.

Should I take a Cladosporium or fungal probiotic supplement for IBS? Not based on this study. The tested strain was a laboratory reference strain never isolated from a patient, gavaged into mice, and no human safety or efficacy trial has been done.

Why would a fungus be more common in sicker patients if it's protective? The authors' leading hypothesis is that increased Cladosporium reflects the body's own attempt to compensate for gut inflammation and pain, an adaptive response that may simply be insufficient to fully reverse symptoms in most patients.

Is this specific to diarrhea-predominant IBS? The human data come entirely from IBS-D patients, so the findings cannot be assumed to apply to constipation-predominant or mixed-type IBS.

References

1. Cheng-Lin Guo, Shang-Qing Zhang, Hao-Nan Zheng, Yan Chi, Hua-Hong Wang (2026). Cladosporium cladosporioides ameliorates visceral hypersensitivity in irritable bowel syndrome-like mice by inhibiting dectin-1 signaling and mast cell activation. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.119605
2. Alejandro Nieto-Patlán, Marcia Campillo-Navarro, Octavio Rodríguez-Cortés, et al. (2015). Recognition of Candida albicans by Dectin-1 induces mast cell activation. Immunobiology. https://doi.org/10.1016/j.imbio.2015.05.005
3. Yu Gu, Guoqiong Zhou, Xiali Qin, Shumin Huang, Bangmao Wang, Hailong Cao (2019). The Potential Role of Gut Mycobiome in Irritable Bowel Syndrome. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2019.01894
4. Xiao-Fang Lu (2015). Role of mast cells in irritable bowel syndrome. World Chinese Journal of Digestology. https://doi.org/10.11569/wcjd.v23.i14.2239